Global /United States /Healthcare /Biotechnology /MAIA

MAIA Biotechnology, Inc.

MAIA

• NYSEAMERICAN: MAIA • Delayed

1.30USD 4%

As of 14 June 2026, MAIA Biotechnology, Inc. has a market cap of $78.87M USD, ranking #27245 globally and #4137 in the United States. It ranks #2448 in the Healthcare sector, and #472 in the Biotechnology industry.

Global Rank

27245

Country Rank

4137

Sector Rank

2448

Industry Rank

472

Key Stats

Market Cap

$78.87MUSD

Enterprise Value

$70.82MUSD

Net Income (TTM)

-$22.4MUSD

PB Ratio

20.3

Company Profile

Country (HQ)

United States

Sector

Healthcare

Industry

Biotechnology

CEO

Vlad Vitoc open_in_new

Employees

Founded

2018

IPO

28 Jul 2022

Website

maiabiotech.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
4%	-4.4%	-0.8%	-53%	-7.1%	-15%	-30%	-47%	-68%

News

MAIA Analyst Forecasts

Markets

Exchange	Ticker	Price	Quotes
NYSE American (NYSEAMERICAN / AMEX) MIC: XASE PRIMARY	MAIA MAIA Biotechnology Inc ISIN: US5526411021 Shares Out.: Shares Outstanding: 60.801M¹ Shares Float: 50.73M² TV: TradingView: AMEX: MAIA SA: Stock Analysis: NYSEAMERICAN: MAIA YF: Yahoo Finance: MAIA GF: Google Finance: NYSEAMERICAN: MAIA NQ: NASDAQ: MAIA BA: Barron's: MAIA MS: Morningstar: XASE: MAIA	1.30 USD	TV: TradingView: AMEX: MAIA SA: Stock Analysis: NYSEAMERICAN: MAIA YF: Yahoo Finance: MAIA GF: Google Finance: NYSEAMERICAN: MAIA NQ: NASDAQ: MAIA BA: Barron's: MAIA MS: Morningstar: XASE: MAIA

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About MAIA Biotechnology, Inc.

MAIA Biotechnology, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the development of targeted immunotherapies for cancer. Its lead product Ateganosine, a telomere-targeting agent currently in clinical development to evaluate its activity in Non-Small Cell Lung Cancer (NSCLC). The company was incorporated in 2018 and is headquartered in Chicago, Illinois.

Similar Companies

Industry: Biotechnology (United States)

Name	Market Cap (USD) diff.	PE	Country
Amgen Inc. NASDAQ: AMGN	$182.42B 231K%	23.9	United States
Gilead Sciences, Inc. NASDAQ: GILD	$159.92B 203K%	19.0	United States
Natera, Inc. NASDAQ: NTRA	$27.6B 35K%	-	United States
IQVIA Holdings Inc. NYSE: IQV	$26.3B 33K%	20.0	United States
United Therapeutics Corp. NASDAQ: UTHR	$25.03B 32K%	20.4	United States
Moderna, Inc. NASDAQ: MRNA	$18.13B 23K%	-	United States

Industry: Biotechnology (Global)

Name	Market Cap (USD) diff.	PE	Country
argenx SE EBR: ARGX	$47.84B 41.39B EUR 61K%	39.9	Netherlands
Samsung Biologics Co.,Ltd. KRX: 207940	$44.84B 68.19T KRW 57K%	35.5	South Korea
CSL Ltd. ASX: CSL	$42.36B 60.27B AUD 54K%	29.3	Australia
Lonza Group AG SIX: LONN	$42.3B 33.71B CHF 54K%	37.2	Switzerland
Celltrion, Inc. KRX: 068270	$28.11B 42.76T KRW 36K%	43.8	South Korea
BioNTech SE NASDAQ: BNTX	$25.69B 32K%	-	Germany

chevron_leftBack